- Conditions
- Breast Neoplasms
- Interventions
- PD0332991, Anastrozole, Goserelin, Surgery (standard of care), Tumor biopsy
- Drug · Procedure
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 84 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2026
- U.S. locations
- 4
- States / cities
- Birmingham, Alabama • Scottsdale, Arizona • Rochester, Minnesota + 1 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 24
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Type I Diabetes
- Interventions
- Oral glucose tolerance test for Phase I
- Procedure
- Lead sponsor
- Scripps Translational Science Institute
- Other
- Eligibility
- 18 Years to 65 Years
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- Started 2013
- U.S. locations
- 1
- States / cities
- San Diego, California
- Conditions
- Metastatic Breast Cancer
- Interventions
- Inavolisib, Phesgo, Placebo, Taxane-based Chemotherapy, Optional Endocrine Therapy of Investigator's Choice
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 230 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2032
- U.S. locations
- 20
- States / cities
- Gilbert, Arizona • Burbank, California • Corona, California + 17 more
- Conditions
- Neoplasms, Breast Neoplasms, Breast Cancer
- Interventions
- AZD8931, anastrozole, Placebo
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 482 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 1
- States / cities
- Lake Success, New York
- Conditions
- Breast Cancer, Cancer of the Breast
- Interventions
- VENTANA MIB-1 Ki67 assay, Oncotype DX® Recurrence Score, PAM50-based Prosigna breast cancer gene signature assay, Anastrozole, Combination anthracycline and/or taxane based treatment
- Device · Drug
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 81 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Locally Advanced Adrenal Gland Pheochromocytoma, Locally Advanced Paraganglioma, Metastatic Adrenal Gland Pheochromocytoma, Metastatic Paraganglioma, Metastatic Parathyroid Gland Carcinoma, Pituitary Gland Carcinoma, Somatostatin Receptor Positive, Stage III Thyroid Gland Medullary Carcinoma AJCC v8, Stage IV Thyroid Gland Medullary Carcinoma AJCC v8, Stage IVA Thyroid Gland Medullary Carcinoma AJCC v8, Stage IVB Thyroid Gland Medullary Carcinoma AJCC v8, Stage IVC Thyroid Gland Medullary Carcinoma AJCC v8, Unresectable Adrenal Gland Pheochromocytoma, Unresectable Paraganglioma
- Interventions
- Lutetium Lu 177 Dotatate
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Metastatic Colorectal Cancer, Metastatic Pancreatic Cancer, Metastatic Ovarian Cancer, Metastatic Breast Carcinoma, Metastatic Endocrine Tumors/ Neuroendocrine Tumors
- Interventions
- Pembrolizumab (Keytruda), Fludarabine, Cyclophosphamide, Aldesleukin, Young TIL
- Drug · Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years to 72 Years
- Enrollment
- 332 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2029
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- PCOS
- Interventions
- DEXA, Magnetic Resonance (MR) Assessment of the Abdomen, MR assessment of Whole Body Fat, Adipose tissue biopsy, Oral glucose tolerance test
- Other · Procedure
- Lead sponsor
- AdventHealth Translational Research Institute
- Other
- Eligibility
- 18 Years to 45 Years · Female only
- Enrollment
- 108 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2025
- U.S. locations
- 1
- States / cities
- Orlando, Florida
- Conditions
- Diabetes Mellitus, Hyperglycemia, Hypoglycemia
- Interventions
- Self blood glucose monitoring and insulin administration, Standard care
- Procedure
- Lead sponsor
- Atlanta VA Medical Center
- Federal
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2007
- U.S. locations
- 1
- States / cities
- Decatur, Georgia
- Conditions
- Osteoporosis, Osteoporosis, Postmenopausal
- Interventions
- Parathyroid Hormone-related Protein, Placebo
- Drug
- Lead sponsor
- University of Pittsburgh
- Other
- Eligibility
- 50 Years to 75 Years · Female only
- Enrollment
- 61 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2005 – 2008
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Adrenal Insufficiency, Growth Disorder, Endocrine Diseases, Metabolic Disease, Bone Diseases, Metabolic
- Interventions
- Not listed
- Lead sponsor
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
- NIH
- Eligibility
- 3 Months to 100 Years
- Enrollment
- 15,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2030
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Insomnia
- Interventions
- Ramelteon, Placebo
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 122 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2004
- U.S. locations
- 29
- States / cities
- Birmingham, Alabama • Jasper, Alabama • Mesa, Arizona + 26 more
- Conditions
- Diabetes Mellitus, Type 1
- Interventions
- Standard of Care, Type 1 Together
- Behavioral
- Lead sponsor
- Nemours Children's Clinic
- Other
- Eligibility
- 12 Years to 17 Years
- Enrollment
- 37 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- Wilmington, Delaware
- Conditions
- Breast Cancer
- Interventions
- Standard Therapy, Local Therapy
- Drug · Procedure
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- Female only
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2027
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Diabetes Mellitus, Cardiovascular Diseases, Insulin Sensitivity/Resistance, Metabolic Disease, Natriuretic Peptides, Metabolism, Energy Expenditure
- Interventions
- Sacubitril, Valsartan 97-103 mg Oral Tablet, Valsartan 160 mg, Intravenous Glucose Tolerance Test, Standardized Meals, Exercise capacity VO2 maximum determination
- Drug · Other · Dietary Supplement
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 200 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2027
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama
- Conditions
- Breast Cancer, Breast Cancer - Female, Breast Carcinoma, ER Positive Breast Cancer, PR-Positive Breast Cancer
- Interventions
- SHIELD portal
- Behavioral
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 18 Years to 49 Years · Female only
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer
- Interventions
- Giredestrant, Fulvestrant, Abemaciclib, Palbociclib, Ribociclib, LHRH Agonist, FoundationOne Liquid CDx Assay (F1LCDx)
- Drug · Diagnostic Test
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,050 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2029
- U.S. locations
- 61
- States / cities
- Daphne, Alabama • Auburn, California • Greenbrae, California + 53 more
- Conditions
- Breast Cancer
- Interventions
- Surveys, Video
- Other
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Metastatic Breast Cancer
- Interventions
- Not listed
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 194 participants
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- East Hanover, New Jersey
- Conditions
- McCune-Albright Syndrome, Fibrous Dysplasia, Intraductal Papillary Mucinous Neoplasm, Diabetes Mellitus
- Interventions
- Hyperinsulinemic Euglycemic Clamp and 2H20, Hyperglycemic Clamp, Oral Glucose Tolerance Test
- Procedure · Diagnostic Test
- Lead sponsor
- Yale University
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2021
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Hypoglycemia
- Interventions
- Continuous Glucose Monitoring, activity monitor, Mixed meal tolerance test, Glucagon Sensitivity Testing, Hypoglycemic Hyperinsulinemic Clamp, analysis of fecal microbiome
- Diagnostic Test
- Lead sponsor
- Joslin Diabetes Center
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 105 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2024
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Cardiovascular Diseases, Metabolic Syndrome, Obesity, Prediabetes, Mental Health Disorders, Endocrine Dysfunction, Type 2 Diabetes Mellitus (T2DM), Chronic Kidney Disease (CKD)
- Interventions
- Blood Work
- Other
- Lead sponsor
- Clindove Research LLC
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 7,000 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2030
- U.S. locations
- 1
- States / cities
- Brooklyn, New York
- Conditions
- Pancreatic Cancer
- Interventions
- Synthetic Human Secretin
- Drug
- Lead sponsor
- Columbia University
- Other
- Eligibility
- 18 Years to 75 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2012
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Type 1 Diabetes Mellitus
- Interventions
- CGM + Family Behavioral Intervention, Standard CGM
- Behavioral · Device
- Lead sponsor
- Jaeb Center for Health Research
- Other
- Eligibility
- 2 Years to 7 Years
- Enrollment
- 143 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 1
- States / cities
- Indianapolis, Indiana